Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: MERIDIA

« Back to Dashboard

Summary for Tradename: MERIDIA

Patents:0
Applicants:1
NDAs:1

Clinical Trials for: MERIDIA

Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects
Status: Completed Condition: Healthy

Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
Status: Completed Condition: Obesity

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
Status: Completed Condition: Obesity

Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients
Status: Active, not recruiting Condition: Obesity

Studying the Effects of Sibutramine on Eating Behavior
Status: Terminated Condition: Obesity

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives
Status: Completed Condition: Obesity; Hypertension

A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
Status: Completed Condition: Obesity

Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
Status: Completed Condition: Obesity

A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)
Status: Completed Condition: Obesity

"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"
Status: Recruiting Condition: Obesity

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott
MERIDIA
sibutramine hydrochloride
CAPSULE;ORAL020632Nov 22, 1997DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MERIDIA

Drugname Dosage Strength RLD Submissiondate
sibutramine hydrochlorideCapsules10 mg and 15 mgMeridia8/14/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc